RB1 and retinoblastoma: For example, in vitro evaluations of LY3295668 and ENMD-2076, both Aurora kinase inhibitors, have been effective against RB1-mutant small cell lung cancer cells [8, 9], and LY3295668 was effective at treating RB1-deficient retinoblastoma in vivo [10].